About Blood Purification:2.2 Impact Factor I 5.8 CiteScore I 0.782 Scimago Journal & Country Rank (SJR)
Record: found
Abstract: found
Article: found
Comparison of 1α-OH-Vitamin D<sub>3</sub> and High Doses of Calcium Carbonate for the Control of Hyperparathyroidism and Hyperaluminemia in Patients on Maintenance Dialysis
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
27 patients on hemodialysis (dialysate aluminium < 0.7 μmol/l for 2 years, and 2 μmol/l
before) whose plasma Ca and PO<sub>4</sub> were adequately controlled for already
6 months by high doses of CaCO<sub>3</sub> alone (mean ± SD: 9 ± 5 g/day), were randomly
divided into 2 groups, a control group (c group) which was kept on the same treatment,
and a group in which CaCO<sub>3</sub> was reduced to 3 g/day but in which plasma Ca
was kept normal due to 1α-OH-vitamin D<sub>3</sub> administration (1 μg/day at the
beginning, 0.3 μg/day after 6 months; 1α group) whereas plasma phosphate was kept
below 6.0 mg/dl because of A1(OH)<sub>3</sub> (2.7–5 g/day). Initially, the 2 groups
were comparable as regards the plasma concentrations of total and ionized Ca, phosphate,
alkaline phosphatases, medium and C-terminal parathyroid hormone (PTH) and aluminium,
but the control group had lower plasma 25-OH-vitamin D (25-OHD.) After 6 months, the
same difference in plasma 25-OHD was found with comparable plasma concentrations of
total and ionized calcium as well as of medium and C-terminal PTH (beta error 1%).
However, plasma concentration of phosphate and the plasma Ca phosphate product, as
well as the plasma aluminium were higher in the 1α group whereas their PCO<sub>3</sub>H
was lower. Although the alkaline phosphatase values were not significantly different
between the 2 groups, they increased only in the control group because of 1 patient
who developed a vitamin-D-deficient osteomalacia (plasma 25-OHD 3 ng/ml), which was
subsequently cured by physiological doses of 25-OHD<sub>3</sub>. The incidence of
transient hypercalcemia (15 vs. 21 episodes) and worsening of soft tissue calcifications
(3 in each group) was the same in the 2 groups.